Related Experiment Video
Updated: Apr 23, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Metabolism of new drug modalities research advances - 2025 year in review
Bin Ma1, Lionel Cheruzel1, Sungjoon Cho1
1Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc, South San Francisco, CA, USA.
Abstract:
New drug modalities (NDMs) continue to redefine the pharmaceutical landscape by addressing "undruggable" targets and providing innovative therapeutics for various diseases. This third annual review summarizes 15 selected publications from 2025 that advance our understanding of NDM metabolism. We focus on four major categories: (1) PROTACs and molecular glues, with an emphasis on biotransformation and chiral stability; (2) Oligonucleotide therapeutics, including in vitro and in vivo metabolism of oligonucleotides as well as a workflow for metabolite identification; (3) Macrocyclic peptides, highlighting throughput enhancements and leader-independent cyclization; and (4) Conjugated drugs, encompassing antibody-drug conjugates (ADCs) and novel Fc-fusion proteins. This collection provides critical insights into metabolism, tissue distribution, and analytical innovations intended to accelerate the transition of these complex modalities from discovery to clinical application.
More Related Videos
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug Biotransformation: Overview
Drug Biotransformation: Overview
Pharmacogenetics of Drug Metabolism: Overview
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Drug Metabolism: Phase II Reactions

